Valeant Pharmaceuticals International Inc. (NYSE:VRX)’s share price fell 0.9% during trading on Friday . The stock traded as low as $22.85 and last traded at $23.28, with a volume of 15,002,748 shares traded. The stock had previously closed at $23.49.

Several brokerages have recently commented on VRX. Guggenheim reaffirmed a “buy” rating and set a $55.00 price target (down previously from $145.00) on shares of Valeant Pharmaceuticals International in a research report on Saturday, March 19th. Rodman & Renshaw reaffirmed a “buy” rating on shares of Valeant Pharmaceuticals International in a research report on Sunday, April 3rd. Wells Fargo & Co. reaffirmed a “sell” rating on shares of Valeant Pharmaceuticals International in a research report on Saturday, April 9th. Mizuho reaffirmed a “sell” rating on shares of Valeant Pharmaceuticals International in a research report on Tuesday, May 31st. Finally, Susquehanna reaffirmed a “hold” rating and set a $105.00 price target on shares of Valeant Pharmaceuticals International in a research report on Sunday, May 29th. Seven equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Valeant Pharmaceuticals International presently has a consensus rating of “Hold” and an average target price of $74.71.

The stock’s market capitalization is $7.98 billion. The company has a 50-day moving average price of $24.10 and a 200-day moving average price of $52.43.

Valeant Pharmaceuticals International (NYSE:VRX) last released its quarterly earnings results on Tuesday, June 7th. The specialty pharmaceutical company reported $1.27 EPS for the quarter, missing the Zacks’ consensus estimate of $1.37 by $0.10. The business had revenue of $2.37 billion for the quarter, compared to analysts’ expectations of $2.34 billion. During the same quarter in the previous year, the business posted $2.36 EPS. The firm’s quarterly revenue was up 9.3% on a year-over-year basis. On average, equities research analysts forecast that Valeant Pharmaceuticals International Inc. will post $6.62 earnings per share for the current fiscal year.

In other news, CEO Joseph C. Papa purchased 202,000 shares of Valeant Pharmaceuticals International stock in a transaction on Friday, June 10th. The shares were purchased at an average cost of $24.48 per share, for a total transaction of $4,944,960.00. Following the completion of the transaction, the chief executive officer now directly owns 2,442,199 shares in the company, valued at $59,785,031.52. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.

Several institutional investors recently made changes to their positions in VRX. Oppenheimer & Co. Inc. raised its position in shares of Valeant Pharmaceuticals International by 51.2% in the fourth quarter. Oppenheimer & Co. Inc. now owns 10,455 shares of the specialty pharmaceutical company’s stock worth $1,062,000 after buying an additional 3,541 shares during the last quarter. Deere & Co. raised its position in shares of Valeant Pharmaceuticals International by 121.1% in the fourth quarter. Deere & Co. now owns 15,011 shares of the specialty pharmaceutical company’s stock worth $1,526,000 after buying an additional 8,222 shares during the last quarter. Napier Park Global Capital US LP bought a new position in shares of Valeant Pharmaceuticals International during the fourth quarter worth about $1,740,000. State of New Jersey Common Pension Fund D bought a new position in shares of Valeant Pharmaceuticals International during the fourth quarter worth about $2,033,000. Finally, Suntrust Banks Inc. raised its position in shares of Valeant Pharmaceuticals International by 237.8% in the fourth quarter. Suntrust Banks Inc. now owns 30,718 shares of the specialty pharmaceutical company’s stock worth $3,122,000 after buying an additional 21,625 shares during the last quarter.

Valeant Pharmaceuticals International, Inc is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.